Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05010629 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Glenn J. Hanna

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Results first posted: Aug 7, 2026
    • Trial arms changed: 1 → 2
    v11
  2. Secondary endpoints: 6 to 7
    • Study arms: 4 to 2
    v10
  3. Primary endpoint revisedv9 Show 5 more changesShow less
    • Enrollment target: estimated 35 to confirmed 32
    • Start date: Sep 14, 2021 to Sep 17, 2021
    • Interventions: 9-ING-41 (Drug), Carboplatin (Drug) to 9-ING-41 (Drug), Carboplatin (Drug), Pembrolizumab (Drug)
    • Secondary endpoints: 7 to 6
    • Study arms: 1 to 4
  4. Primary completion date: Jun 1, 2024 to Feb 14, 2025
    • Study completion date: Aug 30, 2025 to Apr 12, 2027
    v8
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v6
  2. Primary completion date: Jan 1, 2024 to Jun 1, 2024v5
  3. Primary completion date: Sep 30, 2023 to Jan 1, 2024v4
  4. Primary completion date: Sep 30, 2022 to Sep 30, 2023
    • Study completion date: Aug 30, 2024 to Aug 30, 2025
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 1, 2021 to Sep 14, 2021
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: * 9-ING-41 (a GSK-3β inhibitor) * Carboplatin chemotherapy
Trial Details
NCT Number NCT05010629
Lead Sponsor Glenn J. Hanna
Collaborators: Actuate Therapeutics Inc.
Conditions
(from sponsor)		 Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
Related terms Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov